title: Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood.
abstract: To assess the efficacy and tolerability of mycophenolate sodium (MPS) in the therapy of children with chronic non-infectious uveitis.
  
  
  
  Retrospective analysis of 23 children with chronic uveitis, treated with MPS, with a follow-up of at least 6 months. The main outcome measures were time to uveitis reactivation and corticosteroid-sparing effect under MPS treatment. The secondary outcome measures were best-corrected visual acuity (BCVA) and treatment-related side effects.
  
  
  
  From 23 patients included in the study, 2 patients had anterior uveitis, 19 had intermediate uveitis and 2 had panuveitis. The probability of reactivation-free survival after MPS initiation was estimated as 65% at both 1 and 2 years. The probability of discontinuing systemic corticosteroids after 1 year of treatment was 39% and after 2 years 51%. The probability to taper corticosteroids to a daily dosage of ≤0.1 mg/kg after 1 and 2 years was 62% and 85%, respectively. BCVA improved or remained stable in 96% of eyes after 1 year of therapy. Treatment-related side effects were found in nine children (rate: 0.17/patient-year). No therapy discontinuation because of side effects was needed.
  
  
  
  Our data suggest that MPS is useful and well tolerated in children with chronic uveitis. MPS seems to be an effective drug for the treatment of chronic non-infectious uveitis of childhood and may be preferred as a first-line steroid-sparing agent in this form of uveitis.
authors.affiliation: Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
authors.forename: Deshka
authors.initials: D
authors.lastname: Doycheva
authors.affiliation: Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
authors.forename: Manfred
authors.initials: M
authors.lastname: Zierhut
authors.affiliation: Department of Clinical Epidemiology and Applied Biometry, University of Tuebingen, Tuebingen, Germany.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Blumenstock
authors.affiliation: Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
authors.forename: Bianka
authors.initials: B
authors.lastname: Sobolewska
authors.affiliation: Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
authors.forename: Bogomil
authors.initials: B
authors.lastname: Voykov
authors.affiliation: Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
authors.forename: Johanna
authors.initials: J
authors.lastname: Hohmann
authors.affiliation: Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
authors.forename: Martin S
authors.initials: MS
authors.lastname: Spitzer
authors.affiliation: Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Deuter
mesh_terms: D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D002648:Child; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009173:Mycophenolic Acid / Q000008:administration & dosage*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy*; D014792:Visual Acuity
chemical_list: D000903:Antibiotics, Antineoplastic; D009173:Mycophenolic Acid
keywords: Child health (paediatrics); Inflammation; Treatment Medical